BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Trinity Biotech (TRIB) Completes Acquisition Of Research Diagnostics


10/19/2005 5:13:04 PM

DUBLIN, Ireland, March 21 /PRNewswire-FirstCall/ -- Trinity Biotech plc today announced that it has completed the acquisition of Research Diagnostics Inc. ("RDI"), of Flanders, New Jersey.

Trinity Biotech has acquired the business of RDI for US$4.2 million in cash. RDI provides a comprehensive range of immunodiagnostic products to research facilities, pharmaceutical companies, reference laboratories, diagnostic manufacturers, and universities worldwide. The Company's revenue and profit performance has shown consistent growth with sales last year in excess of US$5 million. The acquisition is expected to be accretive in the current financial year.

The range of products provided by RDI is similar to that provided by Fitzgeralds, a company which Trinity acquired in April 2004. Specifically the range includes monoclonal and polyclonal antibodies, antigens, proteins, enzymes and immunochemicals employed in the areas of cancer, cardiac, fertility and infectious disease diagnosis. The operations of RDI will be integrated with those of Fitzgeralds in the coming months and the combined entity will operate on a stand alone basis within the Trinity group.

Ronan O'Caoimh, Trinity Biotech CEO, commented "We are delighted to be deploying our cash resources to this earnings accretive acquisition. RDI is a natural fit with our existing operations in Fitzgerald in that it is particularly strong in supplying product to research facilities worldwide whereas Fitzgerald's focus is on diagnostic manufacturers. There is minimal overlap in the products supplied by both companies. We are confident that the combination of both RDI and Fitzgerald will strengthen Trinity's position in this segment of the life sciences market with combined turnover in excess of US$11 million."

Edward Fitzgerald, Chairman Fitzgerald Industries International, commented "The acquisition of RDI by Trinity will provide Fitzgeralds with access to an alternative customer base and exciting new products for supply to existing Fitzgerald customers. We are very excited at the opportunities this will present to continue the growth profile of our business and to position Fitzgerald and RDI as leading suppliers to the life sciences market."

Trinity Biotech develops, acquires manufactures and markets diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The broad line of over 500 test kits are used to detect infectious diseases, sexually transmitted diseases, blood coagulation disorders, and autoimmune diseases. Trinity is also a significant provider of raw materials to the life science industry. Trinity Biotech sells worldwide in 78 countries through its own salesforces and a network of international distributors and strategic partners. For further information please see the company's website: http://www.trinitybiotech.com/.

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

Trinity Biotech plc

CONTACT: Trinity Biotech plc, Rory Nealon, Tel: +353-1-2769800, E-mail:rory.nealon@trinitybiotech.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->